Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lundbeck’s Vyepti Sales Disappoint But Lower Costs Boost Profitability

Danish Firm Hoping For More From Migraine Drug

Executive Summary

Sales for the migraine product were lower in Q4 than consensus forecasts projected, but reduced costs have pushed yearly earnings beyond expectations.

You may also be interested in...



The Bipolar Big Three: LAIs, Atypical Antipsychotics And Symptom Specific Drugs

Despite the highly genericized nature of the bipolar disorder market, firms have innovated with long-acting injectables, improved atypical antipsychotics and drugs targeting specific symptoms.

Vyepti Sales Disappoint But Lundbeck Sees Growth From Expanded Infusion Center Network

Key brands saw growth in the first half of 2021 despite the company’s overall revenues falling, mainly due to generic competition for Northera.

Lundbeck Set For 'Transformative' Eptinezumab Launch

The Danish drugmaker's four 'strategic brands' – Brintellix, Abilify Maintena, Northera and Rexulti – are selling well. Now the focus is firmly on breaking into the anti-CGRP market with eptinezumab.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC145861

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel